|Title:||Indium-111 oxine complex composition|
|Abstract:||An indium-111 preparation comprises a complex of indium-111 with a quinoline compound carrying an 8-hydroxyl group, e.g. oxine, present in an aqueous medium which also contains a surface active agent to prevent the complex from becoming bound to the surface of the vessel on autoclaving, and optionally a buffer to improve blood cell labelling efficiency. The surface active agent is preferably non-ionic, e.g. a polyoxyethylene sorbitan ester of a fatty acid. The buffer is preferably N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid.|
|Inventor(s):||Kelly; James D. (Buckinghamshire, GB2)|
|Assignee:||The Radiochemical Centre Limited (GB2)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||7909867||Mar 21, 1979|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0017355||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.